9.6200
09-May-25 16:45:00
15 minutes delayed
Stocks
-0.4000
-3.99%
Today's range
9.5700 - 10.5216
ISIN
N/A
Source
NASDAQ
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
31 Mar 2025 07:30:00 By Nasdaq GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 Feb 2025 08:00:00 By Nasdaq GlobeNewswire